How galectins have become multifunctional proteins
- PMID: 31922250
- DOI: 10.14670/HH-18-199
How galectins have become multifunctional proteins
Abstract
Having identified glycans of cellular glycoconjugates as versatile molecular messages, their recognition by sugar receptors (lectins) is a fundamental mechanism within the flow of biological information. This type of molecular interplay is increasingly revealed to be involved in a wide range of (patho)physiological processes. To do so, it is a vital prerequisite that a lectin (and its expression) can develop more than a single skill, that is the general ability to bind glycans. By studying the example of vertebrate galectins as a model, a total of five relevant characteristics is disclosed: i) access to intra- and extracellular sites, ii) fine-tuned gene regulation (with evidence for co-regulation of counterreceptors) including the existence of variants due to alternative splicing or single nucleotide polymorphisms, iii) specificity to distinct glycans from the glycome with different molecular meaning, iv) binding capacity also to peptide motifs at different sites on the protein and v) diversity of modular architecture. They combine to endow these lectins with the capacity to serve as multi-purpose tools. Underscoring the arising broad-scale significance of tissue lectins, their numbers in terms of known families and group members have steadily grown by respective research that therefore unveiled a well-stocked toolbox. The generation of a network of (ga)lectins by evolutionary diversification affords the opportunity for additive/synergistic or antagonistic interplay in situ, an emerging aspect of (ga)lectin functionality. It warrants close scrutiny. The realization of the enormous potential of combinatorial permutations using the five listed features gives further efforts to understand the rules of functional glycomics/lectinomics a clear direction.
References
-
- Ackerman S.J., Corrette S.E., Rosenberg H.F., Bennett J.C., Mastrianni D.M., Nichelson-Weller A., Weller P.F., Chin D.T. and Tenen D.G. (1993). Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). J. Immunol. 150, 456-468. - PubMed
-
- Ahmad N., Gabius H.-J., André S., Kaltner H., Sabesan S., Roy R., Liu B., Macaluso F. and Brewer C.F. (2004). Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J. Biol. Chem. 279, 10841- 10847. - PubMed
-
- Akahani S., Nangia-Makker P., Inohara H., Kim H.-R.C. and Raz A. (1997). Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 57, 5272-5276. - PubMed
-
- Amano M., Eriksson H., Manning J.C., Detjen K.M., André S., Nishimura S.-I., Lehtiö J. and Gabius H.-J. (2012). Tumour suppressor p16INK4a: anoikis-favouring decrease in N/O-glycan/cell surface sialylation by down-regulation of enzymes in sialic acid biosynthesis in tandem in a pancreatic carcinoma model. FEBS J. 279, 4062- 4080. - PubMed
-
- André S., Kojima S., Yamazaki N., Fink C., Kaltner H., Kayser K. and Gabius H.-J. (1999). Galectins-1 and -3 and their ligands in tumor biology. Non-uniform properties in cell-surface presentation and modulation of adhesion to matrix glycoproteins for various tumor cell lines, in biodistribution of free and liposome-bound galectins and in their expression by breast and colorectal carcinomas with/without metastatic propensity. J. Cancer Res. Clin. Oncol. 125, 461-474. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous